Principal Scientist, Oncology
Christoph Eberle currently works as a principal scientist at Charles River's Worcester facility in Massachusetts, where he expanded flow cytometry capabilities of the in vivo pharmacology/oncology team. In his role, he oversees immunophenotyping of tissue samples collected from various mouse models (syngeneic and humanized) to include method development and T-cell isolations for adoptive transfers. He regularly liaises with clients to provide PD study management, scientific discussion, data analysis and interpretation. Dr. Eberle independently has been supporting BD and strategic efforts for the Worcester discovery site. Trained as biochemist, he specialized in cell-based assay development and validation across pre-clinical and clinical operations. In 2008, he received his PhD in Organic Chemistry from the University of Bremen (Germany). Dr. Eberle maintains a professional membership with the Institute of Clinical Research (ICR) in the United Kingdom and is also involved in the International Society for Advancement of Cytometry (ISAC). Prior to joining Charles River in 2017, he held positions at Envigo, Eurofins Central Laboratory and the University Medical Center Göttingen (UMG).